Brief: Aequus Announces Expansion Of Market Opportunity For Its Long Acting Anti-Nausea Transdermal Patch
July 19 (Reuters) - Aequus Pharmaceuticals Inc AQS.V :
* AEQUUS ANNOUNCES EXPANSION OF MARKET OPPORTUNITY FOR ITS
LONG
ACTING ANTI-NAUSEA TRANSDERMAL PATCH
* AEQUUS - PLANS TO LAUNCH AQS1303 IN COUNTRIES WHERE
ORIGINAL
ORAL FORM APPROVED, ACCELERATED PATH TO APPROVAL MAY EXIST FOR
REFORMULATED PRODUCTS
* AEQUUS PHARMACEUTICALS - FOLLOWING REVIEW BY MHRA &
COMMISSION
ON CHM IN JUNE 2018, XONVEA EXPECTED TO BE AVAILABLE IN UK LATER
IN 2018
Source text for Eikon: ID:nGNXb96dMC
Further company coverage: AQS.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aequus Pharmaceuticals
See all newsBrief: Aequus Pharmaceutical Canada Pauses Sales Of Evolve Intensive Eyedrops, Gel In Canada
Brief: Aequus Announces Financing To Support Launch Of Zimed Preservative Free (Bimatoprost 0.03%) And Board Update
Brief: Aequus Announces Health Canada Notice Of Compliance For Zimed® Preservative Free
Brief: Aequus Announces Sandoz Contract Expiry At Year End And Expected Health Canada Approval For Zimed® Pf (Preservative Free)
Brief: Aequus Resumes Trading On TSX Venture Exchange